Form 4: IGM Biosciences Director Acquires Shares Through Stock Award

IGM Biosciences director M Kathleen Behrens acquired 3,078 shares of common stock through a stock award, while also holding indirect ownership of a significant number of shares through various trusts.

Summary

• M Kathleen Behrens, a director at IGM Biosciences, acquired 3,078 shares of common stock on December 31, 2024, as part of a quarterly retainer.
• The shares were acquired through fully vested restricted stock units (RSUs), with each RSU representing one share of IGM Biosciences common stock.
• The transaction was reported on January 3, 2025.
• Behrens also indirectly owns 330,700 shares through the KBW 2005 Trust, 29,807 shares through the Non-Exempt Trust for Patrick R. Wilsey, and 29,806 shares through the Non-Exempt Trust for Shannon K. Wilsey.
• These indirect holdings are managed through trusts where Behrens serves as a trustee.

Sentiment

Score: 6

Explanation: The document is a routine SEC filing related to a director's stock acquisition. It is neither particularly positive nor negative, reflecting standard corporate governance practices.

Positives

• The acquisition of shares by a director can be seen as a positive sign of confidence in the company's future.
• The use of RSUs as compensation aligns the director's interests with those of the shareholders.

Industry Context

This is a routine filing related to insider transactions, which is common for publicly traded companies. It reflects the compensation practices of IGM Biosciences and the ownership structure of its directors.

Comparison to Industry Standards

• The use of restricted stock units (RSUs) as part of director compensation is a common practice among publicly traded biotechnology companies.
• The level of indirect ownership through trusts is not unusual for directors with significant personal wealth.
• The reporting of these transactions via SEC Form 4 is a standard regulatory requirement for all publicly traded companies in the US.

Stakeholder Impact

• The transaction has a minor positive impact on shareholders as it aligns director interests with company performance.

Key Dates

Keywords

IGM Biosciences, director, stock acquisition, restricted stock units, RSUs, beneficial ownership, trust, insider trading, SEC Form 4